RECCE PHARMACEUTICALS LTD

Recce Pharmaceuticals (RCE.AX) offers a low‑cap, high‑reward play in synthetic antibiotics, with a promising pre‑clinical pipeline poised for FDA/TGA accelerated approval.

Recce’s modest 1.43% rise masks a low‑capital, pre‑clinical antibiotic venture—high risk, low confidence, and minimal investor conviction.

Recce Pharma’s 20.7% rally and Phase III trial data spotlight its synthetic antibiotic pipeline, offering investors fresh upside in the fight against resistant infections.